Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

N David Gill


  • Director at Evolus Inc. (EOLS), 2019-06-15
  • Director at Y-Mabs Therapeutics Inc. (YMAB), 2019-06-14
  • Director at Melinta Therapeutics Inc. W (MLNT), 2019-06-12
  • Director at Strata Skin Sciences Inc. (SSKN), 2018-07-17
  • Director at Histogenics Corp (HSGX), 2018-06-19
  • President And Cfo at Endochoice Holdings Inc. (GI), 2016-11-23
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
EOLS $13.65 2,000 Director 5,000 2019-06-13 Filing
EOLS $12.77 3,000 Director 3,000 2018-12-14 Filing
MLNT $6.09 5,000 Director 6,000 2018-05-25 Filing
HSGX $1.81 3,000 Director 14,000 2017-08-16 Filing
HSGX $1.68 3,000 Director 11,000 2017-05-16 Filing